Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03179917 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

A Phase 2 study of Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
22
Enrollment target
9
Study locations

NCT03179917 is a Phase 2 study of Hodgkin Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 22 participants, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (87% lower). The trial reports 9 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03179917, a Phase 2 study of Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
22 participants
Enrollment target
9
Study locations

Study Summary

This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma. The purpose of this study is to determine how effective combining the research drug, pembrolizumab, with a targeted form of radiation therapy known as involved site radiotherapy can be in patients with relapsed or refractory early stage classical Hodgkin lymphoma. The goal is to see whether this treatment strategy can cure a significant number of patients with relapsed or refractory early stage classical Hodgkin lymphoma while avoiding the toxicity of either a large radiation field or further chemotherapy and stem cell transplant.

Conditions Studied

Hodgkin Lymphoma

Interventions

  • DRUG Pembrolizumab
  • RADIATION Involved Site Radiation Therapy

Study Locations (9)

New York

  • Memorial Sloan Kettering Commack - Commack
  • Memorial Sloan Kettering Westchester - Harrison
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau - Uniondale

New Jersey

  • Memorial Sloan Kettering at Basking Ridge - Basking Ridge
  • Memorial Sloan Kettering Monmouth - Middletown
  • Memorial Sloan Kettering Bergen - Montvale

Florida

  • University of Miami - Miami

Pennsylvania

  • Abramson Cancer Center at University of Pennsylvania (Data Collection Only) - Philadelphia

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2017-06-08
Est. Completion 2026-06
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03179917

The ClinicalTrials.gov registry entry for NCT03179917 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 166-participant average among 71 other Hodgkin Lymphoma trials with a reported enrollment target (87% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT03179917 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, Florida.

Frequently Asked Questions

What is clinical trial NCT03179917 about?

NCT03179917 is a clinical study titled "Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma". This study is being done to test the safety and effectiveness of pembrolizumab followed by radiation therapy in Hodgkin lymphoma. The purpose of this study is to determine how effective combining the research drug, pembrolizumab, with a targeted form of radiation therapy known as involved site radi...

What is the current status of trial NCT03179917?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2017-06-08. Estimated completion is 2026-06.

What conditions does trial NCT03179917 study?

This clinical trial studies the following conditions: Hodgkin Lymphoma.

What interventions are being tested in trial NCT03179917?

The interventions under investigation include: Pembrolizumab (DRUG), Involved Site Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT03179917?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03179917 being conducted?

This trial has 9 study locations across Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hodgkin Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hodgkin Lymphoma

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.